ClinicalTrials.gg
TerminatedNCT05960578Updated Oct 19, 2026Results posted

Golimumab and Apalutamide for the Treatment of Castration-Resistant Prostate Cancer, TRAMP Study

A Phase 2 interventional study of Apalutamide and Biopsy in Metastatic Castration-Resistant Prostate Carcinoma, Prostate Adenocarcinoma and Stage IV Prostate Cancer AJCC v8, sponsored by University of Washington. Terminated at 1 site in United States. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-19.

Sponsored by University of Washington · Phase 2, Interventional, and Treatment

How we know

Why this study was terminated
The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.
Updated Oct 19, 2026Now TerminatedResults posted+3 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
8
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 70 studies testing apalutamide in Prostatic Neoplasms — 14 open to participants now, 36 under way, 12 of them phase 3. apalutamide · Prostatic Neoplasms.

Enrollment
63rd of 70
8 · median 81
Started
2024
with 3 others
Phase 2
37 of 70
8 open now
Registered
66th of 70
by date
Lead sponsor
2 of 70
University of Washington

Among the 70 studies testing apalutamide in Prostatic Neoplasms, this one is the 63rd largest by enrollment, is one of 4 that started in 2024, is one of 37 in phase 2, and was the 66th registered.

Prostatic Neoplasms

7,058 studies on the registry are indexed under Prostatic Neoplasms; 1,582 are open to participants now.

Browse Prostatic Neoplasms studies →

Open to participants now

14 of the 70 studies testing apalutamide in Prostatic Neoplasms are open now, in 11 countries. Recruiting first, the newest first:

9 more — sign in →

By country, each count listing its studies:

All 14 open studies →

About apalutamide

apalutamide: first FDA approval 2018 (ERLEADA), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 1,236 Prostatic Neoplasms studies recruiting now, 933 (75%) set no upper age limit and 77 (6%) stop at 75 or younger; 67 take children under 18; 82 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 70 studies testing apalutamide in Prostatic Neoplasms, or all of them as a file.
02

Study summary

This phase II trial tests how well golimumab and apalutamide work in treating patients with castration resistant prostate cancer. Golimumab is in a class of medications called tumor necrosis factor (TNF) inhibitors. It works by blocking the action of TNF, a substance in the body that causes inflammation. Apalutamide is in a class of medications called androgen receptor inhibitors. It works by blocking the effects of androgen (a male reproductive hormone) to stop the growth and spread of cancer cells. Giving golimumab and apalutamide may work better in treating patients with castration-resistant prostate cancer.

Read the detailed description

OUTLINE:

Patients receive golimumab subcutaneously (SC) every 4 weeks for 6 doses and apalutamide orally (PO) daily. Treatment with apalutamide continues in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy at baseline and during cycle 4. Patients also undergo computed tomography (CT) scans or magnetic resonance imaging (MRI), prostate-specific membrane antigen (PSMA) positron emission tomography (PET), bone scan, and collection of blood samples throughout the study.

After completion of study treatment, patients are followed every 3 months.

03

Conditions studied

  • Metastatic Castration-Resistant Prostate Carcinoma
  • Prostate Adenocarcinoma
  • Stage IV Prostate Cancer AJCC v8

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • History of diagnosed prostatic adenocarcinoma
  • Participants must have progressed on no more than one novel hormonal therapy (NHT) by PSA or radiographic criteria (per Prostate Cancer Working Group 3 [PCWG3] or [RECIST] version [v]1.1) and a castrate serum testosterone level (i.e., ≤ 50 ng/dL). If progressive disease by radiographic criteria, PSA must be ≥ 2ng/ml. PSA progression will be defined as at least two successive PSA rises above the nadir, separated by ≥ 1 week, with the last determination having a value of ≥ 2 ng/mL. NHTs include but are not limited to either abiraterone, enzalutamide, darolutamide, or apalutamide. (Biosimilar or generic agents may be allowed at the discretion of the principal investigator [PI].) Note: prior NHT exposure that did not result in disease progression will not be counted as prior line, i.e., patient's that completed prior abiraterone course in the localized setting, patients that changed NHT due to toxicity or financial toxicity
  • Participants must have previously progressed on a novel hormonal therapy (NHT) by PSA or radiographic criteria (per PCWG3 or RECIST v1.1). NHTs include but are not limited to either abiraterone, enzalutamide, darolutamide, or apalutamide. (Biosimilar or generic agents may be allowed at the discretion of the principal investigator [PI].) Note: prior NHT exposure that did not result in disease progression will not be counted as prior line, i.e., patient's that completed prior abiraterone course in the localized setting, patients that changed NHT due to toxicity or financial toxicity
  • Participants may have received one prior line of taxane chemotherapy in any setting
  • Participants must be >= 18 years of age prior to signing
  • (ECOG) performance status score =\< 2
  • >= 9.0 g/dL, independent of transfusion and/or growth factors within 3 months prior to randomization
  • count >= 100,000 x 10\^9/uL independent of transfusion and/or growth factors within 3 months prior to randomization
  • >= 1.5 x 10\^3/mL
  • Serum albumin >= 3.0 g/dL
  • Serum creatinine =\< 1.5 mg/dL
  • Serum potassium >= 3.5 mmol/L
  • Serum total \< 1.5 x (ULN) (Note: In subjects with Gilbert's syndrome, if total bilirubin is > 1.5 x ULN, measure direct and indirect bilirubin and if direct bilirubin is =\< 1.5 x ULN, subject may be eligible)
  • (AST), alanine aminotransferase (ALT) and alkaline phosphatase =\< 1.5 x ULN
  • Agrees to use a condom (even men with vasectomies) and another effective method of if he is having sex with a woman of or agrees to use a condom if he is having sex with a woman who is pregnant while on study drug and for 3 months following the last dose of study drug. Must also agree not to donate sperm during the study and for 3 months after receiving the last dose of study drug
  • Medications known to lower the seizure threshold (see list under prohibited meds) must be discontinued or substituted at least 4 weeks prior to study entry
  • Have had no known recent close contact with a person with active tuberculosis (TB) or, if there has been such contact, will be referred to a physician specializing in TB to undergo additional evaluation
  • Participants must sign an informed consent form (ICF) indicating that they understand the purpose of, and procedures required for, the study and are willing to participate in the study

Exclusion criteria

Exclusion Criteria:

  • Subjects may not be receiving other agents within 14 days prior to enrollment
  • Subjects with predominant small cell or neuroendocrine variant prostate cancer on most recent standard of care
  • Evidence of serious and/or unstable pre-existing medical, psychiatric or other condition that could interfere with patient safety
  • Symptomatic central nervous system (CNS) . Treated will be allowed if these are stable for at least 8 weeks prior to enrollment
  • Uncontrolled or active infection, including:

    • infection (acute or chronic) as defined according to the American Society of Clinical Oncology guidelines, or infection (anti-hepatitis C virus [HCV] antibody positive and HCV-ribonucleic acid [RNA] quantitation positive)
    • Recent serious infection (e.g., requiring IV antibiotics or hospitalization within last two months)
    • Herpes zoster infection within 2 months of screening
    • History of active granulomatous infection, including histoplasmosis, or coccidioidomycosis
    • (HIV antibody positive)
    • Active or untreated latent tuberculosis
    • History of infected joint prosthesis or received antibiotics for suspected infection of a joint prosthesis in the past five years, if that prosthesis has not been removed or replaced
    • Less serious infections (e.g., acute upper respiratory tract infection, simple urinary tract infection) need not be considered exclusionary at the discretion of the investigator
  • Has impaired wound healing capacity defined as current skin/decubitus ulcers, chronic leg ulcers, known gastric ulcers, or unhealed incisions
  • Major surgery within 2 weeks of the first dose, or will not have fully recovered from surgery, or has surgery planned during the time the subject is expected to participate in the study or within 2 weeks after the last dose of study drug administration (Note: subjects with planned surgical procedures to be conducted under local anesthesia may participate)
  • Co-administration of other TNF-alpha inhibitors or disease-modifying anti-rheumatic drugs (DMARDS) for the treatment of rheumatoid arthritis or other rheumatologic condition. (Note: prior exposure to TNF-alpha inhibitors is allowed for non-rheumatologic disease (e.g., SARS-CoV-2) if > 5 half-lives prior to study enrollment)
  • Any other issue that would impair the ability of the subject to receive or tolerate the planned treatment at the investigational site, to understand or any condition for which, in the opinion of the investigator, participation would not be in the best interest of the subject (e.g., compromise the well-being) or that could prevent, limit, or confound the protocol-specified assessments
  • Presence of significant cardiovascular disease including (NYHA) class II-IV heart failure, uncontrolled arrhythmia, myocardial infarction (MI) or stroke within 6 months
  • History of disorder, including multiple sclerosis or optic neuritis, lupus or lupus-like Syndrome
  • to any biologics or known allergies or reactions to murine, chimeric, or human proteins, monoclonal antibodies (mAbs), or antibody fragments
  • Have a transplanted organ (with the exception of a corneal transplant performed > 3 months prior to first administration of study drug)
  • Currently has a or a history of malignancy within 3 years before screening (with the exception of prostate cancer, treated superficial bladder cancer, or a nonmelanoma skin cancer that has been adequately treated with no evidence of recurrence for at least 3 months prior to the administration of the first study intervention
  • Immune deficiency syndrome (e.g., severe combined immunodeficiency syndrome [SCIDS], T cell deficiency syndromes, B cell deficiency syndromes, and chronic granulomatous disease)
  • Have had a Bacille Calmette-Guerin (BCG) vaccination within 12 months of screening. Patients must agree not to receive BCG vaccination during the study and within 16 weeks after the last administration of study intervention
  • Known allergies, hypersensitivity, or intolerance to apalutamide or its
  • Gastrointestinal disorder affecting absorption
  • History of seizure or any condition that in the opinion of the investigator may predispose to seizure or treatment with drugs known to lower the seizure threshold within 4 weeks prior to starting treatment with apalutamide
Terms in these criteria, in plain language(26)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Hemoglobin (Hb)

The protein in red blood cells that carries oxygen. A low level is anemia, which can cause tiredness and breathlessness. Measured in g/dL or g/L (9 g/dL is 90 g/L).

Platelets

Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Bilirubin

A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.

Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Washout period

A planned gap after a treatment, so that its effects can lessen before the study treatment or a study assessment. Ask the study team and the doctor who prescribed it before changing any medicine.

NYHA class (heart failure)

The New York Heart Association’s four classes of how much heart failure limits physical activity.

I
No limits: ordinary activity causes no undue tiredness or breathlessness.
II
Slight limits: comfortable at rest, ordinary activity causes symptoms.
III
Marked limits: comfortable at rest, less than ordinary activity causes symptoms.
IV
Symptoms even at rest; any activity makes them worse.

Studies set their own limit — many outside heart failure leave out class III–IV, while heart failure studies may ask for a particular class. Check the class this study names.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
8 participants (actual)

Study arms

  • Experimental
    Treatment (golimumab, apalutamide)

    Patients receive golimumab SC every 4 weeks for 6 doses and apalutamide PO daily. Treatment with apalutamide continues in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy at baseline and during cycle 4. Patients also undergo CT scans or MRI, PSMA PET, bone scan, and collection of blood samples throughout the study.

    Drug: Apalutamide · Procedure: Biopsy · Procedure: Biospecimen Collection · Procedure: Computed Tomography · Drug: Golimumab · Procedure: Magnetic Resonance Imaging · Procedure: PSMA PET Scan · Procedure: Bone Scan

Interventions

  • Given PO

    Also known as: ARN 509, ARN-509, ARN509, Erleada, JNJ 56021927, JNJ-56021927

  • ProcedureBiopsy

    Undergo tumor biopsy

    Also known as: BIOPSY_TYPE, Bx

  • ProcedureBiospecimen Collection

    Undergo collection of blood samples

    Also known as: Biological Sample Collection, Biospecimen Collected, Specimen Collection

  • ProcedureComputed Tomography

    Undergo CT scan

    Also known as: CAT, CAT Scan, Computed Axial Tomography, Computerized Axial Tomography, Computerized axial tomography (procedure), Computerized Tomography, CT, CT Scan, tomography

  • Given SC

    Also known as: CNTO 148, Immunoglobulin G1, Anti-(Human Tumor Necrosis Factor Alpha) (Human Monoclonal CNTO 148 Gamma-1-Chain), Disulfide with Human Monoclonal CNTO 148 Kappa-Chain, Dimer

  • ProcedureMagnetic Resonance Imaging

    Undergo MRI

    Also known as: Magnetic Resonance, Magnetic resonance imaging (procedure), Magnetic Resonance Imaging Scan, Medical Imaging, Magnetic Resonance / Nuclear Magnetic Resonance, MR, MR Imaging, MRI, MRI Scan, NMR Imaging, NMRI, Nuclear Magnetic Resonance Imaging

  • ProcedurePSMA PET Scan

    Undergo PSMA PET

    Also known as: Prostate-specific Membrane Antigen PET, PSMA PET, PSMA-Positron emission tomography

  • ProcedureBone Scan

    Undergo bone scan

    Also known as: Bone Scintigraphy

06

What researchers measure

Primary outcomes

  1. Prostate Specific Antigen (PSA)50 Response Rate

    Defined by at least a 50% decline in PSA from baseline, in subjects with castrate resistant prostate cancer after combination treatment with TNF-alpha alpha blockade (golimumab) and AR antagonism (apalutamide).

    Time frame: Up to 12 weeks

Secondary outcomes

  1. Objective Response Rate

    Will determine objective response rate of measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria for soft tissue metastases. Target Lesions were assessed as follows: CR: Disappearance of all target lesions. All pathological lymph nodes short axis reduced to \<10 mm. PR: Decrease by ≥30% in the sum of diameters. PD: Increase by ≥20% in the sum of diameters with an absolute increase of ≥5 mm, or appearance of ≥1 new lesion. SD: Neither sufficient shrinkage for PR nor sufficient increase for PD. Non-Target Lesions were assessed as follows: CR: Disappearance of all non-target lesions, normalization of tumor markers, and all lymph nodes must be non-pathologic in size (\<10 mm short axis). Non-CR/Non-PD: Persistence of ≥1 non-target lesion and/or maintenance of tumor marker level above the normal limits. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

    Time frame: Up to 14.5 months

  2. Radiographic Progression Free Survival (PFS)

    The duration of radiographic PFS (rPFS) will be calculated for all treated subjects with soft tissue and/or bone disease as the time from the first dose of IP to the first objective evidence of radiographic progression or death from any cause, whichever occurs first. Radiographic disease progression is defined as progressive disease by RECIST for soft tissue and PCWG3 for bone disease. The PFS will be estimated using the Kaplan-Meier method for the treated population.

    Time frame: Up to 14.5 months

  3. PSA PFS

    The interval between enrollment and the date of documented PSA progression. Progression will be declared if patient has documented to have a testosterone less than 50 ng/dL. In cases where a testosterone level has not been obtained and patient has not had an orchiectomy, progressive disease will be deemed if patient had a documented rise in PSA on luteinizing hormone-releasing hormone analogue therapy. Progression free survival curves will be generated using Kaplan-Meier method.

    Time frame: Up to 14 months

  4. PSA Doubling Time

    The rate of PSA doubling will be calculated from nadir to confirmed PSA progression after 2 subsequent rises 1 week apart using standard calculators

    Time frame: Up to 14 months

  5. Time to Subsequent Antineoplastic Therapy

    The interval between enrollment and the date of documented initiation of next therapy.

    Time frame: Up to 16 months

  6. Incidence of Adverse Events

    Assess the incidence and severity of adverse events according to the National Cancer Institute - Common Terminology Criteria for Adverse Events version 5.0.

    Time frame: Up to 30 days after final receipt of golimumab and/or apalutamide (up to 15 months)

07

Results

Posted Oct 19, 2026

Participant flow

Participant flow — Overall Study
MilestoneTreatment (Golimumab, Apalutamide)
Started8
Completed8
Not completed0

Outcome measures

PrimaryProstate Specific Antigen (PSA)50 Response Rate

Defined by at least a 50% decline in PSA from baseline, in subjects with castrate resistant prostate cancer after combination treatment with TNF-alpha alpha blockade (golimumab) and AR antagonism (apalutamide).

Time frame:
Up to 12 weeks
Reported as:
Count of participants · Participants
Prostate Specific Antigen (PSA)50 Response Rate
ParticipantsTreatment (Golimumab, Apalutamide)
Number of Subjects who had a PSA50 response0
Number of Subjects who did not have a PSA50 response8
SecondaryObjective Response Rate

Will determine objective response rate of measurable or evaluable disease as per Response Evaluation Criteria in Solid Tumors version 1.1 criteria for soft tissue metastases. Target Lesions were assessed as follows: CR: Disappearance of all target lesions. All pathological lymph nodes short axis reduced to \<10 mm. PR: Decrease by ≥30% in the sum of diameters. PD: Increase by ≥20% in the sum of diameters with an absolute increase of ≥5 mm, or appearance of ≥1 new lesion. SD: Neither sufficient shrinkage for PR nor sufficient increase for PD. Non-Target Lesions were assessed as follows: CR: Disappearance of all non-target lesions, normalization of tumor markers, and all lymph nodes must be non-pathologic in size (\<10 mm short axis). Non-CR/Non-PD: Persistence of ≥1 non-target lesion and/or maintenance of tumor marker level above the normal limits. Progressive Disease (PD): Appearance of one or more new lesions and/or unequivocal progression of existing non-target lesions.

Time frame:
Up to 14.5 months
Reported as:
Count of participants · Participants
Objective Response Rate
ParticipantsTreatment (Golimumab, Apalutamide)
Number of Subjects who had an objective response0
Number of Subjects who did not have an objective response5
SecondaryRadiographic Progression Free Survival (PFS)

The duration of radiographic PFS (rPFS) will be calculated for all treated subjects with soft tissue and/or bone disease as the time from the first dose of IP to the first objective evidence of radiographic progression or death from any cause, whichever occurs first. Radiographic disease progression is defined as progressive disease by RECIST for soft tissue and PCWG3 for bone disease. The PFS will be estimated using the Kaplan-Meier method for the treated population.

Time frame:
Up to 14.5 months
Reported as:
Median · Months
Radiographic Progression Free Survival (PFS)
MonthsTreatment (Golimumab, Apalutamide)
Radiographic Progression Free Survival (PFS)2.83 (2.7 to NA)
SecondaryPSA PFS

The interval between enrollment and the date of documented PSA progression. Progression will be declared if patient has documented to have a testosterone less than 50 ng/dL. In cases where a testosterone level has not been obtained and patient has not had an orchiectomy, progressive disease will be deemed if patient had a documented rise in PSA on luteinizing hormone-releasing hormone analogue therapy. Progression free survival curves will be generated using Kaplan-Meier method.

Time frame:
Up to 14 months
Reported as:
Median · Months
PSA PFS
MonthsTreatment (Golimumab, Apalutamide)
PSA PFS3.62 (2 to NA)
SecondaryPSA Doubling Time

The rate of PSA doubling will be calculated from nadir to confirmed PSA progression after 2 subsequent rises 1 week apart using standard calculators

Time frame:
Up to 14 months
Reported as:
Mean · Months
PSA Doubling Time
MonthsTreatment (Golimumab, Apalutamide)
PSA Doubling Time2.8 (0.7 to 6.9)
SecondaryTime to Subsequent Antineoplastic Therapy

The interval between enrollment and the date of documented initiation of next therapy.

Time frame:
Up to 16 months
Reported as:
Median · Months
Time to Subsequent Antineoplastic Therapy
MonthsTreatment (Golimumab, Apalutamide)
Time to Subsequent Antineoplastic Therapy4.8 (3.8 to NA)
SecondaryIncidence of Adverse Events

Assess the incidence and severity of adverse events according to the National Cancer Institute - Common Terminology Criteria for Adverse Events version 5.0.

Time frame:
Up to 30 days after final receipt of golimumab and/or apalutamide (up to 15 months)
Reported as:
Count of participants · Participants
Incidence of Adverse Events
ParticipantsTreatment (Golimumab, Apalutamide)
Number of Subjects who experienced an AE of any grade related to study therapy7
Number of Subjects who did not experience an AE of any grade related to study therapy1
Number of Subjects who experienced a Grade 3 adverse event3
Number of Subjects who did not experience a Grade 3 adverse event5
Number of Subjects who had a Grade 4 or Grade 5 adverse event0

Adverse events

Collected over AEs will be monitored and recorded in study-specific case report forms (CRFs) from time a subject has signed and dated an Informed Consent Form (ICF) until 30 days after the last documented use of the product under study within the study, up to 15 months total.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Treatment (Golimumab, Apalutamide)1/8 (12.5%)3/8 (37.5%)8/8 (100%)
Most frequent serious events
Most frequent serious events
EventTreatment (Golimumab, Apalutamide)
Rash maculo-papularSkin and subcutaneous tissue disorders1/8
PurpuraSkin and subcutaneous tissue disorders1/8
Pain in extremityMusculoskeletal and connective tissue disorders1/8
UrticariaSkin and subcutaneous tissue disorders1/8
Most frequent other events
Showing 10 of 39
Most frequent other events
EventTreatment (Golimumab, Apalutamide)
ArthralgiaMusculoskeletal and connective tissue disorders2/8
AnorexiaMetabolism and nutrition disorders2/8
Maculopapular RashSkin and subcutaneous tissue disorders2/8
FatigueGeneral disorders2/8
DyspneaRespiratory, thoracic and mediastinal disorders2/8
Hair LossSkin and subcutaneous tissue disorders2/8
MyalgiaMusculoskeletal and connective tissue disorders1/8
BursitisMusculoskeletal and connective tissue disorders1/8
DiverticulitisGastrointestinal disorders1/8
PurpuraSkin and subcutaneous tissue disorders1/8

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)Treatment (Golimumab, Apalutamide)
<=18 years0
Between 18 and 65 years2
>=65 years6
Sex: Female, Male
Sex: Female, Male(Participants)Treatment (Golimumab, Apalutamide)
Female0
Male8
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Treatment (Golimumab, Apalutamide)
Hispanic or Latino0
Not Hispanic or Latino7
Unknown or Not Reported1
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Treatment (Golimumab, Apalutamide)
American Indian or Alaska Native0
Asian0
Native Hawaiian or Other Pacific Islander0
Black or African American0
White8
More than one race0
Unknown or Not Reported0
Treatment with prior NHT (novel hormone therapy)
Treatment with prior NHT (novel hormone therapy)(Participants)Treatment (Golimumab, Apalutamide)
Abiraterone2
Enzalutamide5
Darolutamide1
Apalutamide0
Prior taxane therapies
Prior taxane therapies(Participants)Treatment (Golimumab, Apalutamide)
Received taxane chemotherapy0
Has not received taxane chemotherapy8
Baseline PSA
Baseline PSA(ng/mL)Treatment (Golimumab, Apalutamide)
Subject 12.48
Subject 23.38
Subject 31.04
Subject 46.18
Subject 5123.76
Subject 67.81
Subject 72.71
Subject 844.72
08

Study locations

1 site
  • Fred Hutch/University of Washington Cancer Consortium
    Seattle, Washington 98109, United States
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Ran from May 2024 to primary completion in Jul 2025, 14 months.

Results were first posted in Oct 2026, 1 year 2 months after primary completion.

Completion moved once since we started tracking on Sep 25, 2026: Apr 2027 → Apr 2026, on Oct 19, 2026.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Jul 10, 2023
First posted
Jul 27, 2023
StartActual
May 23, 2024
Primary completionActual
Jul 29, 2025
CompletionActual
Apr 14, 2026was Apr 2027
Results first posted
Oct 19, 2026
Last update
Oct 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Terminated The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.
changed Oct 19, 2026
Results
Results posted
posted Oct 19, 2026
Study completion
Apr 14, 2027→Apr 14, 2026 (actual)
Oct 19, 2026
Primary outcomes
1 edited
What changed in the outcomes
  • EditedProstate specific antigenSpecific Antigen (PSA)50 response rateResponse RateTime frame: Up to 12 weeks
Oct 19, 2026
Secondary outcomes
4 edited, 2 time frame changed
What changed in the outcomes
  • EditedObjective response rateResponse RateTime frame: Up to 4 years → Up to 14.5 months
  • EditedRadiographic progression free survivalProgression Free Survival (PFS)Time frame: Up to 4 years → Up to 14.5 months
  • EditedTime to subsequent antineoplastic therapySubsequent Antineoplastic TherapyTime frame: Up to 4 years → Up to 16 months
  • EditedIncidence of adverse eventsAdverse EventsTime frame: Up to 30 days after final receipt of golimumab administration → Up to 30 days after final receipt of golimumab and/or apalutamide (up to 15 months)
  • Time framePSA PFSUp to 4 years → Up to 14 months
  • Time framePSA Doubling TimeUp to 4 years → Up to 14 months
Oct 19, 2026
Show all 1 update
  1. Oct 19, 2026
    Active, not recruiting→Terminated
    Why stopped The trial was ended sooner than expected due to a combination of factors, including slow accrual, lower than anticipated benefit to patients, and loss of funding from the study sponsor.
    Results posted
    Study completion Apr 14, 2027→Apr 14, 2026 (now actual)
    Primary outcomes 1 edited
    What changed in the outcomes
    • EditedProstate specific antigenSpecific Antigen (PSA)50 response rateResponse RateTime frame: Up to 12 weeks
    Secondary outcomes 4 edited, 2 time frame changed
    What changed in the outcomes
    • EditedObjective response rateResponse RateTime frame: Up to 4 years → Up to 14.5 months
    • EditedRadiographic progression free survivalProgression Free Survival (PFS)Time frame: Up to 4 years → Up to 14.5 months
    • EditedTime to subsequent antineoplastic therapySubsequent Antineoplastic TherapyTime frame: Up to 4 years → Up to 16 months
    • EditedIncidence of adverse eventsAdverse EventsTime frame: Up to 30 days after final receipt of golimumab administration → Up to 30 days after final receipt of golimumab and/or apalutamide (up to 15 months)
    • Time framePSA PFSUp to 4 years → Up to 14 months
    • Time framePSA Doubling TimeUp to 4 years → Up to 14 months
    + 3 other changes: index terms, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT05960578
Responsible party
Ruben Raychaudhuri, MD (Assistant Professor, University of Washington) — Principal investigator
First posted
Jul 27, 2023
Start date
May 23, 2024
Primary completion
Jul 29, 2025
Completion
Apr 14, 2026
Results posted
Oct 19, 2026
Last update
Oct 19, 2026

Study contacts

Ruben Raychaudhuri, MD
principal investigator · Fred Hutch/University of Washington Cancer Consortium

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Aug 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Apalutamide · Golimumab

Start the discussion